-
1
-
-
33644543761
-
Expanding insights of mitochondrial dysfunction in Parkinson's disease
-
DOI 10.1038/nrn1868, PII N1868
-
Abou-Sleiman PM, Muqit MMK, Wood NW, et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006;7:207-219 (Pubitemid 43292466)
-
(2006)
Nature Reviews Neuroscience
, vol.7
, Issue.3
, pp. 207-219
-
-
Abou-Sleiman, P.M.1
Muqit, M.M.K.2
Wood, N.W.3
-
2
-
-
33847105184
-
Advances in the treatment of Parkinson's disease
-
DOI 10.1016/j.pneurobio.2006.11.009, PII S0301008206001511
-
Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson's disease. Prog Neurobiol 2007;81:29-44 (Pubitemid 46282270)
-
(2007)
Progress in Neurobiology
, vol.81
, Issue.1
, pp. 29-44
-
-
Singh, N.1
Pillay, V.2
Choonara, Y.E.3
-
3
-
-
57349093766
-
Levodopa for the treatment of Parkinson's Disease
-
• This review provides a discussion of mechanism, benefits and problems related to LD therapy from a clinical point of view
-
LeWitt PA. Levodopa for the treatment of Parkinson's Disease. N Engl J Med 2008;359:2468-2476 • This review provides a discussion of mechanism, benefits and problems related to LD therapy from a clinical point of view.
-
(2008)
N Engl J Med
, vol.359
, pp. 2468-2476
-
-
LeWitt, P.A.1
-
4
-
-
0033934604
-
Entacapone and selegiline with L-dopa in patients with Parkinson's disease: An interaction study
-
DOI 10.1016/S1353-8020(00)00012-2, PII S1353802000000122
-
Lyytinen J, Kaakkola S, Gordin A, et al. Entacapone and selegiline with L-dopa patients with Parkinson's disease: an interaction study. Parkinsonism Relat Disord 2000;6:215-222 (Pubitemid 30438779)
-
(2000)
Parkinsonism and Related Disorders
, vol.6
, Issue.4
, pp. 215-222
-
-
Lyytinen, J.1
Kaakkola, S.2
Gordin, A.3
Kultalahti, E.-R.4
Teravainen, H.5
-
5
-
-
0036798244
-
Dopaminergic substitution in Parkinson's disease
-
DOI 10.1517/14656566.3.10.1393
-
Müller T. Dopaminergic substitution in Parkinson's Disease. Expert Opin Pharmacother 2002;2:1393-1403 (Pubitemid 35174871)
-
(2002)
Expert Opinion on Pharmacotherapy
, vol.3
, Issue.10
, pp. 1393-1403
-
-
Muller, T.1
-
6
-
-
0031106236
-
New strategies with dopaminergic drugs: Modified formulations of levodopa and novel agonists
-
DOI 10.1006/exnr.1996.6381
-
Goetz CG. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists. Exp Neurol 1997;144:17-20 (Pubitemid 27149596)
-
(1997)
Experimental Neurology
, vol.144
, Issue.1
, pp. 17-20
-
-
Goetz, C.G.1
-
8
-
-
26444597591
-
Does levodopa slow or hasten the rate of progression of Parkinson's Disease?
-
Parkinson Study Group
-
Fahn S. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's Disease? J Neurol 2005;252:37-42
-
(2005)
J Neurol
, vol.252
, pp. 37-42
-
-
Fahn, S.1
-
9
-
-
7944236868
-
Clinical advantages of COMT inhibition with entacapone - A review
-
DOI 10.1007/s00702-004-0190-3, Parkinson's Research in Progress
-
Gordin A, Kaakkola S, Teräväinen H. Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 2004;111:1343-1363 (Pubitemid 39468395)
-
(2004)
Journal of Neural Transmission
, vol.111
, Issue.10-11
, pp. 1343-1363
-
-
Gordin, A.1
Kaakkola, S.2
Teravainen, H.3
-
10
-
-
67349157116
-
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily
-
published on line 20 February 2009, doi:10.1007/s00228-009-0622-y
-
Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009: published on line 20 February 2009, doi:10.1007/s00228-009-0622-y
-
(2009)
Eur J Clin Pharmacol
-
-
Kuoppamäki, M.1
Korpela, K.2
Marttila, R.3
-
11
-
-
33947364316
-
Entacapone improves complex movement performance in patients with Parkinson's disease
-
DOI 10.1016/j.jocn.2006.02.008, PII S0967586806001810
-
Müller T, Erdmann C, Muhlack S, et al. Entacapone improves complex movement performance in patients with Parkinson's disease. J Clin Neurosci 2007;14:424-428 (Pubitemid 46453184)
-
(2007)
Journal of Clinical Neuroscience
, vol.14
, Issue.5
, pp. 424-428
-
-
Muller, T.1
Erdmann, C.2
Muhlack, S.3
Bremen, D.4
Przuntek, H.5
Woitalla, D.6
-
12
-
-
3843063551
-
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: Results of a large multicentre open-label study
-
Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm 2004;111:1053-1063 (Pubitemid 39037126)
-
(2004)
Journal of Neural Transmission
, vol.111
, Issue.8
, pp. 1053-1063
-
-
Onofrj, M.1
Thomas, A.2
Vingerhoets, F.3
Martin, W.4
Gimenez-Roldan, S.5
Azulay, J.-P.6
Bernhard, G.7
Schmidt, W.8
Markabi, S.9
-
13
-
-
0031773064
-
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
-
Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309-1314 (Pubitemid 28520549)
-
(1998)
Neurology
, vol.51
, Issue.5
, pp. 1309-1314
-
-
Rinne, U.K.1
Larsen, J.P.2
Siden, A.3
Worm-Petersen, J.4
-
14
-
-
0031028464
-
Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
-
Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-87 (Pubitemid 27039521)
-
(1997)
Neurology
, vol.48
, Issue.1
, pp. 81-87
-
-
Kurth, M.C.1
Adler, C.H.2
St Hilaire, M.3
Singer, C.4
Waters, C.5
Lewitt, P.6
Chernik, D.A.7
Dorflinger, E.E.8
Yoo, K.9
-
15
-
-
0030880324
-
Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients
-
Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428
-
(1997)
J Neurol Neurosurg Psychiatry
, vol.63
, pp. 421-428
-
-
Baas, H.1
Beiske, A.G.2
Ghika, J.3
-
16
-
-
0030778373
-
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
-
DOI 10.1002/ana.410420511
-
Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997;42:747-755 (Pubitemid 27481547)
-
(1997)
Annals of Neurology
, vol.42
, Issue.5
, pp. 747-755
-
-
Kieburtz1
-
17
-
-
0028286186
-
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
-
Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919 (Pubitemid 24158809)
-
(1994)
Neurology
, vol.44
, Issue.5
, pp. 913-919
-
-
Nutt, J.G.1
Woodward, W.R.2
Beckner, R.M.3
Stone, C.K.4
Berggren, K.5
Carter, J.H.6
Gancher, S.T.7
Hammerstad, J.P.8
Gordin, A.9
-
18
-
-
34848821970
-
Tolcapone: An efficacy and safety review
-
Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review. Clin Neuropharmacol 2007;30:287-294
-
(2007)
Clin Neuropharmacol
, vol.30
, pp. 287-294
-
-
Olanow, C.W.1
Watkins, P.B.2
-
19
-
-
20544431978
-
Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy
-
DOI 10.1002/mds.20457
-
Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005;20:3-10 (Pubitemid 40846905)
-
(2005)
Movement Disorders
, vol.20
, Issue.SUPPL. 11
-
-
Olanow, C.W.1
Jankovic, J.2
-
20
-
-
41549097751
-
Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: Implications from a clinical and patient perspective
-
Brooks DJ. Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 2008;4:39-47
-
(2008)
Neuropsychiatr Dis Treat
, vol.4
, pp. 39-47
-
-
Brooks, D.J.1
-
21
-
-
0023722336
-
Controlled-release Sinemet (CR-4): A double-blind crossover study in patients with fluctuating Parkinson's disease
-
Ahlskog JE, Muenter MD, Mcmanis PG. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 1988;63:867-886
-
(1988)
Mayo Clin Proc
, vol.63
, pp. 867-886
-
-
Ahlskog, J.E.1
Muenter, M.D.2
Mcmanis, P.G.3
-
22
-
-
0023920586
-
Controlled-release levodopa/carbidopa. III. Sinemet CR5 treatment response fluctuations in Parkinson's disease
-
Cedarbaum JM, Hoey M, Kutt H, et al. Controlled-release levodopa/carbidopa. III. Sinemet CR5 treatment response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:168-173
-
(1988)
Clin Neuropharmacol
, vol.11
, pp. 168-173
-
-
Cedarbaum, J.M.1
Hoey, M.2
Kutt, H.3
-
23
-
-
0023616607
-
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease
-
Cedarbaum JM, Breck L, Kutt H, et al. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology 1987;37:1607-1612
-
(1987)
Neurology
, vol.37
, pp. 1607-1612
-
-
Cedarbaum, J.M.1
Breck, L.2
Kutt, H.3
-
24
-
-
9044245701
-
Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients
-
Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996;93:14-20 (Pubitemid 26035679)
-
(1996)
Acta Neurologica Scandinavica
, vol.93
, Issue.1
, pp. 14-20
-
-
Dupont, E.1
Andersen, A.2
Boas, J.3
Boisen, E.4
Borgmann, R.5
Helgetveit, A.C.6
Kjaer, M.O.7
Kristensen, T.N.8
Mikkelsen, B.9
Pakkenberg, H.10
Presthus, J.11
Stien, R.12
Worm-Petersen, J.13
Buch, D.14
-
25
-
-
8044229410
-
Comparison of immediate-release and controlled release Carbidopa/Levodopa in Parkinson's disease. a multicenter 5-year study
-
Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-27 (Pubitemid 27037728)
-
(1997)
European Neurology
, vol.37
, Issue.1
, pp. 23-27
-
-
Block, G.1
Liss, C.2
Reines, S.3
Irr, J.4
Nibbelink, D.5
Aarli, J.6
Aguilar, M.7
Ahrens, S.8
Bakheit, A.9
Baumel, B.10
Bertoni, J.11
Capildeo, R.12
Castro-Caldas, A.13
Deza, L.14
Donaldson, I.15
Franck, G.16
Fusillo, J.17
Gauthier, S.18
Gershanik, O.19
Granerus, A.K.20
Hauser, R.A.21
Hennessey, K.22
Hutton, J.T.23
Joffe, R.24
Koller, W.25
Last, B.26
Lewitt, P.27
Mamoli, B.28
Manyam, B.29
Mark, M.30
Nakano, K.31
Nausieda, P.32
Otero, E.33
Paulson, G.34
Pinter, M.35
Reich, S.36
Rodnitzky, R.37
Sage, J.38
Sampaio, C.39
Smith, B.40
Teravainen, H.41
Tetrud, J.42
Tolosa, E.43
Ulm, G.44
Valesco, F.45
more..
-
26
-
-
0033595549
-
Immediate-release and controlled-release carbidopa/levodopa in PD: A 5- Year randomized multicenter study
-
Koller WC, Hutton JT, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999;53:1012-1019 (Pubitemid 29442117)
-
(1999)
Neurology
, vol.53
, Issue.5
, pp. 1012-1019
-
-
Koller, W.C.1
Hutton, J.T.2
Tolosa, E.3
Capilldeo, R.4
-
27
-
-
0029732865
-
Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation
-
Pappert EJ, Goetz CG, Niederman F, et al. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996;47:493-495 (Pubitemid 26422542)
-
(1996)
Neurology
, vol.47
, Issue.6
, pp. 1493-1495
-
-
Pappert, E.J.1
Goetz, C.G.2
Niederman, F.3
Ling, Z.D.4
Stebbins, G.T.5
Carvey, P.M.6
-
28
-
-
0030071016
-
Levodopa stability in solution: Time course, environmental effects, and practical recommendations for clinical use
-
DOI 10.1002/mds.870110106
-
Pappert EJ, Buhrfiend C, Lipton JW, et al. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord 1996;11:24-26 (Pubitemid 26008559)
-
(1996)
Movement Disorders
, vol.11
, Issue.1
, pp. 24-26
-
-
Pappert, E.J.1
Buhrfiend, C.2
Lipton, J.W.3
Carvey, P.M.4
Stebbins, G.T.5
Goetz, C.G.6
-
29
-
-
0028071369
-
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa
-
DOI 10.1002/mds.870090416
-
Metman LV, Hoff J, Mouradian MM, et al. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994;9:463-465 (Pubitemid 24238378)
-
(1994)
Movement Disorders
, vol.9
, Issue.4
, pp. 463-465
-
-
Metman, L.V.1
Hoff, J.2
Mouradian, M.M.3
Chase, T.N.4
-
32
-
-
20144388439
-
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: An exploratory study
-
DOI 10.1001/archneur.62.4.601
-
Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005;62:601-605 (Pubitemid 40489893)
-
(2005)
Archives of Neurology
, vol.62
, Issue.4
, pp. 601-605
-
-
Zappia, M.1
Annesi, G.2
Nicoletti, G.3
Arabia, G.4
Annesi, F.5
Messina, D.6
Pugliese, P.7
Spadafora, P.8
Tarantino, P.9
Carrideo, S.10
Civitelli, D.11
De Marco, E.V.12
Ciro-Candiano, I.C.13
Gambardella, A.14
Quattrone, A.15
-
33
-
-
4644314827
-
Levodopa in the treatment of Parkinson's disease: Current controversies
-
DOI 10.1002/mds.20243
-
Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005 (Pubitemid 39302831)
-
(2004)
Movement Disorders
, vol.19
, Issue.9
, pp. 997-1005
-
-
Olanow, C.W.1
Agid, Y.2
Mizuno, Y.3
Albanese, A.4
Bonucelli, U.5
Damier, P.6
De Yebenes, J.7
Gershanik, O.8
Guttman, M.9
Grandas, F.10
Hallett, M.11
Hornykiewicz, O.12
Jenner, P.13
Katzenschlager, R.14
Langston, W.J.15
Lewitt, P.16
Melamed, E.17
Mena, M.A.18
Michel, P.P.19
Mytilineou, C.20
Obeso, J.A.21
Poewe, W.22
Quinn, N.23
Raisman-Vozari, R.24
Rajput, A.H.25
Rascol, O.26
Sampaio, C.27
Stocchi, F.28
more..
-
34
-
-
1842575746
-
Management of motor complications in Parkinson's disease
-
Dewey JRB. Management of motor complications in Parkinson's disease. Neurology 2004;62:S3-7
-
(2004)
Neurology
, vol.62
-
-
Dewey, J.R.B.1
-
35
-
-
20444489689
-
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
-
DOI 10.1002/mds.20458
-
Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20:S11-6 (Pubitemid 40846906)
-
(2005)
Movement Disorders
, vol.20
, Issue.SUPPL. 11
-
-
Jankovic, J.1
-
36
-
-
34547191858
-
Medical management of levodopa-associated motor complications in patients with Parkinson's disease
-
DOI 10.2165/00023210-200721080-00005
-
Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's Disease. CNS Drugs 2007;21:677-692 (Pubitemid 47121793)
-
(2007)
CNS Drugs
, vol.21
, Issue.8
, pp. 677-692
-
-
Jankovic, J.1
Stacy, M.2
-
37
-
-
0036869650
-
Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
-
DOI 10.1002/mds.10244
-
McColl CD, Reardon KA, Shiff M, et al. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord 2002;17:1227-1234 (Pubitemid 36041336)
-
(2002)
Movement Disorders
, vol.17
, Issue.6
, pp. 1227-1234
-
-
McColl, C.D.1
Reardon, K.A.2
Shiff, M.3
Kempster, P.A.4
-
38
-
-
4243094853
-
Long term motor complications of levodopa: Clinical features, mechanisms, and management strategies
-
DOI 10.1136/pgmj.2003.013912
-
Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J 2004;80:452-458 (Pubitemid 39108037)
-
(2004)
Postgraduate Medical Journal
, vol.80
, Issue.946
, pp. 452-458
-
-
Thanvi, B.R.1
Lo, T.C.N.2
-
39
-
-
33344469306
-
Pharmacokinetic optimisation in the treatment of Parkinson's disease: An update
-
DOI 10.2165/00003088-200645020-00001
-
Nyholm D. Pharmacokinetic optimization in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45:109-136 • An authoritative overview of the strategies for optimization of the treatment of PD, with a focus on pharmacokinetics of LD and DA agonists. (Pubitemid 43290827)
-
(2006)
Clinical Pharmacokinetics
, vol.45
, Issue.2
, pp. 109-136
-
-
Nyholm, D.1
-
40
-
-
0030970473
-
Using liquid levodopa in the treatment of Parkinson's disease. a practical guide
-
Kurth MC. Using liquid levodopa in the treatment of Parkinson's disease: a practical guide. Drugs Aging 1997;10:332-340 (Pubitemid 27202084)
-
(1997)
Drugs and Aging
, vol.10
, Issue.5
, pp. 332-340
-
-
Kurth, M.C.1
-
41
-
-
20844454214
-
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: A clinical and pharmacokinetic study
-
DOI 10.1001/archneur.62.6.905
-
Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910 (Pubitemid 40973452)
-
(2005)
Archives of Neurology
, vol.62
, Issue.6
, pp. 905-910
-
-
Stocchi, F.1
Vacca, L.2
Ruggieri, S.3
Olanow, C.W.4
-
42
-
-
0031780594
-
Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease
-
Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97:75-83 (Pubitemid 28254914)
-
(1998)
Acta Neurologica Scandinavica
, vol.97
, Issue.3
, pp. 175-183
-
-
Nilsson, D.1
Hansson, L.-E.2
Johansson, K.3
Nystrom, C.4
Paalzow, L.5
Aquilonius, S.-M.6
-
43
-
-
33845427430
-
Intravenous levodopa administration in humans based on a two-compartment kinetic model
-
DOI 10.1016/j.jneumeth.2006.07.010, PII S016502700600327X
-
Gordon M, Markhamc J, Hartlein JM, et al. Intravenous levodopa administration in humans based on a two-compartment kinetic model. J Neurosci Methods 2007;159:300-307 (Pubitemid 44908654)
-
(2007)
Journal of Neuroscience Methods
, vol.159
, Issue.2
, pp. 300-307
-
-
Gordon, M.1
Markham, J.2
Hartlein, J.M.3
Koller, J.M.4
Loftin, S.5
Black, K.J.6
-
44
-
-
34548819330
-
The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease
-
DOI 10.1016/j.parkreldis.2007.06.005, PII S1353802007001071
-
Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13:13-17 (Pubitemid 47444538)
-
(2007)
Parkinsonism and Related Disorders
, vol.13
, Issue.SUPPL. SEPT
-
-
Nyholm, D.1
-
45
-
-
20844454214
-
Infusion of levodopa methyl ester in patients with advanced PD: A clinical and pharmacokinetic study
-
Stocchi F, Vacca L, Ruggieri S, et al. Infusion of levodopa methyl ester in patients with advanced PD: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910
-
(2005)
Arch Neurol
, vol.62
, pp. 905-910
-
-
Stocchi, F.1
Vacca, L.2
Ruggieri, S.3
-
46
-
-
0022474704
-
Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: Preliminary observations
-
Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-265 (Pubitemid 16044214)
-
(1986)
Annals of Neurology
, vol.20
, Issue.2
, pp. 262-265
-
-
Kurlan, R.1
Rubin, A.J.2
Miller, C.3
-
47
-
-
0023937322
-
Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism
-
DOI 10.1002/ana.410240116
-
Sage JI, Trooskin S, Sonsalla PK, et al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-89 (Pubitemid 18171381)
-
(1988)
Annals of Neurology
, vol.24
, Issue.1
, pp. 87-89
-
-
Sage, J.I.1
Trooskin, S.2
Sonsalla, P.K.3
Heikkila, R.4
Duvoisin, R.C.5
-
48
-
-
0024319943
-
Jejunal delivery of levodopa methylester
-
Ruggieri S, Stocchi F, Carta A, et al. Jejunal delivery of levodopa methylester. Lancet 1989;8653:45-46
-
(1989)
Lancet
, vol.8653
, pp. 45-46
-
-
Ruggieri, S.1
Stocchi, F.2
Carta, A.3
-
49
-
-
0031906233
-
Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease
-
DOI 10.1002/mds.870130222
-
Syed N, Murphy J, Zimmerman T, et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-338 (Pubitemid 28127812)
-
(1998)
Movement Disorders
, vol.13
, Issue.2
, pp. 336-338
-
-
Syed, N.1
Murphy, J.2
Zimmerman Jr., T.3
Mark, M.H.4
Sage, J.I.5
-
50
-
-
0027518164
-
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations
-
Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993;43:1698-1703
-
(1993)
Neurology
, vol.43
, pp. 1698-1703
-
-
Kurth, M.C.1
Tetrud, J.W.2
Tanner, C.M.3
-
51
-
-
67649128110
-
-
Duodopa® website. Available from: Last accessed 6 October 2008
-
Duodopa® website. Available from: www.duodopa.com [Last accessed 6 October 2008]
-
-
-
-
52
-
-
12544252127
-
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
-
Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223
-
(2005)
Neurology
, vol.64
, pp. 216-223
-
-
Nyholm, D.1
Nilsson Remahl, A.I.2
Dizdar, N.3
-
53
-
-
34447545480
-
Duodenal levodopa infusion for advanced Parkinson's disease: 12-Month treatment outcome
-
DOI 10.1002/mds.21500
-
Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-1149 (Pubitemid 47067225)
-
(2007)
Movement Disorders
, vol.22
, Issue.8
, pp. 1145-1149
-
-
Antonini, A.1
Isaias, I.U.2
Canesi, M.3
Zibetti, M.4
Mancini, F.5
Manfredi, L.6
Dal Fante, M.7
Lopiano, L.8
Pezzoli, G.9
-
54
-
-
34047239617
-
Duodenal levodopa infusion for the treatment of Parkinson's disease
-
DOI 10.1517/14656566.8.5.657
-
Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-664 (Pubitemid 46547018)
-
(2007)
Expert Opinion on Pharmacotherapy
, vol.8
, Issue.5
, pp. 657-664
-
-
Samanta, J.1
Hauser, R.A.2
-
55
-
-
0024384156
-
Continuous levodopa infusions to treat complex dystonia in Parkinson's disease
-
Sage JL, Mchale DM, Sonsalla P, et al. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology 1989;39:888-891 (Pubitemid 19170409)
-
(1989)
Neurology
, vol.39
, Issue.7
, pp. 888-891
-
-
Sage, J.I.1
McHale, D.M.2
Sonsalla, P.3
Vitagliano, D.4
Heikkila, R.E.5
-
56
-
-
0038389152
-
Optimizing levodopa pharmacokinetics: Intestinal infusion versus oral sustained-release tablets
-
DOI 10.1097/00002826-200305000-00010
-
Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing Levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-163 (Pubitemid 36676295)
-
(2003)
Clinical Neuropharmacology
, vol.26
, Issue.3
, pp. 156-163
-
-
Nyholm, D.1
Askmark, H.2
Gomes-Trolin, C.3
Knutson, T.4
Lennernas, H.5
Nystrom, C.6
Aquilonius, S.-M.7
-
57
-
-
41749084435
-
Enteral levodopa/carbidopa infusion in advanced Parkinson disease: Long-term exposure
-
Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73
-
(2008)
Clin Neuropharmacol
, vol.31
, pp. 63-73
-
-
Nyholm, D.1
Lewander, T.2
Johansson, A.3
-
58
-
-
0034093920
-
Transdermal absorption of L-Dopa from a new system composed of two separate layers of L-Dopa and hydrogel in rats
-
DOI 10.1081/DDC-100101294
-
Iwase H, Sudo J, Terui J, et al. Transdermal absorption of L-dopa from a new system composed of two separate layers of L-dopa and hydrogel in rats. Drug Dev Ind Pharm 2000;26:755-759 (Pubitemid 30397330)
-
(2000)
Drug Development and Industrial Pharmacy
, vol.26
, Issue.7
, pp. 755-759
-
-
Iwase, H.1
Sudo, J.-I.2
Terui, J.3
Kakuno, K.4
Watanabe, T.5
Takayama, K.6
Nagai, T.7
-
59
-
-
0036742384
-
Improved stability and release control of levodopa and metaraminol using ion exchange fibers and transdermal iontophoresis
-
Kankkunen T, Huupponen I, Lahtinen K, et al. Improved stability and release control of levodopa and metaraminol using ion exchange fibers and transdermal iontophoresis. Eur J Pharm Sci 2002;16:273-280
-
(2002)
Eur J Pharm Sci
, vol.16
, pp. 273-280
-
-
Kankkunen, T.1
Huupponen, I.2
Lahtinen, K.3
-
60
-
-
0025200701
-
Levodopa delivery from controlled-release polymer matrix: Delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats
-
Sabel BA, Dominiak P, Haeuser W, et al. Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats. J Pharmacol Exp Ther 1990;255:914-922
-
(1990)
J Pharmacol Exp Ther
, vol.255
, pp. 914-922
-
-
Sabel, B.A.1
Dominiak, P.2
Haeuser, W.3
-
61
-
-
0015855006
-
L-dopa level in plasma, primary condition for the kinetic effect
-
Birkmayer W, Danielcyk W, Neumayer E, et al. L-dopa level in plasma, primary condition for the kinetic effect. J Neural Transm 1973;34:133-143
-
(1973)
J Neural Transm
, vol.34
, pp. 133-143
-
-
Birkmayer, W.1
Danielcyk, W.2
Neumayer, E.3
-
62
-
-
0023727878
-
The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats
-
DOI 10.1023/A:1015946114321
-
Leppert PS, Cortese M, Fix JA. The effects of carbidopa dose and time and route of administration on systemic L-Dopa levels in rats. Pharm Res 1988;5:587-591 (Pubitemid 18259216)
-
(1988)
Pharmaceutical Research
, vol.5
, Issue.9
, pp. 587-591
-
-
Leppert, P.S.1
Cortese, M.2
Fix, J.A.3
-
63
-
-
0019863875
-
Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs
-
DOI 10.1002/jps.2600700705
-
Sasahara K, Nitanai T, Habara T, et al. Dosage form design for improvement of bioavailability of levodopa IV: possible causes of low bioavailability of oral levodopa in dogs. J Pharm Sci 1981;70:730-733 (Pubitemid 11059041)
-
(1981)
Journal of Pharmaceutical Sciences
, vol.70
, Issue.7
, pp. 730-733
-
-
Sasahara, K.1
Nitanai, T.2
Habara, T.3
-
64
-
-
0023807258
-
Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa
-
Hutton JH, Morris JL, Gustavo CR. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. Neurology 1988;45:861-864 (Pubitemid 18191123)
-
(1988)
Archives of Neurology
, vol.45
, Issue.8
, pp. 861-864
-
-
Hutton, J.T.1
Morris, J.L.2
Roman, G.C.3
Imke, S.C.4
Elias, J.W.5
-
65
-
-
0017703270
-
Improved delivery through biological membranes. 4. Prodrugs of L Dopa
-
DOI 10.1021/jm00221a014
-
Bordor N, Sloan KB, Higuchi T, et al. Improved delivery through biological membranes 4: prodrugs of L-dopa. J Med Chem 1977;20:1435-1445 (Pubitemid 8209552)
-
(1977)
Journal of Medicinal Chemistry
, vol.20
, Issue.11
, pp. 1435-1445
-
-
Bodor, N.1
Sloan, K.B.2
Higuchi, T.3
Sasahara, K.4
-
66
-
-
33947201622
-
Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms
-
DOI 10.1016/j.ijpharm.2006.10.018, PII S0378517306008842
-
Goole J, Vanderbist F, Amighi K. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms. Int J Pharm 2007;334:35-41 (Pubitemid 46420403)
-
(2007)
International Journal of Pharmaceutics
, vol.334
, Issue.1-2
, pp. 35-41
-
-
Goole, J.1
Vanderbist, F.2
Amighi, K.3
-
67
-
-
0028805325
-
Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug
-
Wang H, Lee J, Tsai M, et al. Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug. Bioorg Med Chem Lett 1995;5:2195-2198
-
(1995)
Bioorg Med Chem Lett
, vol.5
, pp. 2195-2198
-
-
Wang, H.1
Lee, J.2
Tsai, M.3
-
69
-
-
0021340573
-
L-Dopa methyl ester - A candidate for chronic systemic delivery of L-dopa in Parkinson's disease
-
Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-Dopa methyl ester - a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol 1984;7:89-98 (Pubitemid 14138570)
-
(1984)
Clinical Neuropharmacology
, vol.7
, Issue.1
, pp. 89-98
-
-
Cooper, D.R.1
Marrel, C.2
Testa, B.3
-
70
-
-
85012490929
-
A lymphotropic prodrug of L-dopa: Synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3, 4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol
-
Garzon-Aburbeh A, Poupaert JH, Claesen M, et al. A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3, 4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol. J Med Chem 1986;29:687-691
-
(1986)
J Med Chem
, vol.29
, pp. 687-691
-
-
Garzon-Aburbeh, A.1
Poupaert, J.H.2
Claesen, M.3
-
71
-
-
0023582840
-
L-Dopa esters as potential prodrugs: Effect on brain concentration of dopamine metabolites in reserpinized mice
-
Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice. J Pharm Pharmacol 1987;39:809-818 (Pubitemid 18012990)
-
(1987)
Journal of Pharmacy and Pharmacology
, vol.39
, Issue.10
, pp. 809-818
-
-
Cooper, D.R.1
Marrel, C.2
Van De Waterbeemd, H.3
Testa, B.4
Jenner, P.5
Marsden, C.D.6
-
72
-
-
0023225184
-
L-Dopa esters as potential prodrugs: Behavioural activity in experimental models of Parkinson's disease
-
Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J Pharm Pharmacol 1987;39:627-635 (Pubitemid 17116308)
-
(1987)
Journal of Pharmacy and Pharmacology
, vol.39
, Issue.8
, pp. 627-635
-
-
Cooper, D.R.1
Marrel, C.2
Van De Waterbeemd, H.3
-
73
-
-
0024956728
-
A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine
-
Ihara M, Tsuchiya Y, Sawasaki Y, et al. New potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl) alanine. J Pharm Sci 1989;78:525-529 (Pubitemid 20099187)
-
(1989)
Journal of Pharmaceutical Sciences
, vol.78
, Issue.7
, pp. 525-529
-
-
Ihara, M.1
Tsuchiya, Y.2
Sawasaki, Y.3
Hisaka, A.4
Takehana, H.5
Tomimoto, K.6
Yano, M.7
-
74
-
-
0034686406
-
Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa
-
DOI 10.1016/S0960-894X(00)00249-3, PII S0960894X00002493
-
Cingolani GM, Di Stefano A, Mosciatti B, et al. Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2, 5-diketomorpholine as potential prodrug of L-dopa. Bioorg Med Chem Lett 2000;10:1385-1388 (Pubitemid 30391975)
-
(2000)
Bioorganic and Medicinal Chemistry Letters
, vol.10
, Issue.12
, pp. 1385-1388
-
-
Cingolani, G.M.1
Di Stefano, A.2
Mosciatti, B.3
Napolitani, F.4
Giorgioni, G.5
Ricciutelli, M.6
Claudi, F.7
-
75
-
-
0026766041
-
Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease
-
Stocchi F, Ruggieri S, Carta A, et al. Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease. Mov Disord 1992;7:249-256
-
(1992)
Mov Disord
, vol.7
, pp. 249-256
-
-
Stocchi, F.1
Ruggieri, S.2
Carta, A.3
-
76
-
-
0030006032
-
Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease
-
DOI 10.1002/ana.410390321
-
Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996;39:400-404 (Pubitemid 26100768)
-
(1996)
Annals of Neurology
, vol.39
, Issue.3
, pp. 400-404
-
-
Djaldetti, R.1
Melamed, E.2
-
78
-
-
49449113969
-
Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs
-
More SS, Vince R. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs. J Med Chem 2008;51:4581-4588
-
(2008)
J Med Chem
, vol.51
, pp. 4581-4588
-
-
More, S.S.1
Vince, R.2
-
79
-
-
37349122146
-
Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease
-
DOI 10.1021/jm701225u
-
Rosini M, Andrisano V, Bartolini M, et al. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J Med Chem 2007;50:6446-6449 (Pubitemid 350309081)
-
(2007)
Journal of Medicinal Chemistry
, vol.50
, Issue.26
, pp. 6446-6449
-
-
Bolognesi, M.L.1
Cavalli, A.2
Valgimigli, L.3
Bartolini, M.4
Rosini, M.5
Andrisano, V.6
Recanatini, M.7
Melchiorre, C.8
-
80
-
-
52449092612
-
New L-Dopa codrugs as potential antiparkinson agents
-
Sozio P, Iannitelli A, Cerasa LS, et al. New L-Dopa codrugs as potential antiparkinson agents. Arch Pharm 2008;341:412-417
-
(2008)
Arch Pharm
, vol.341
, pp. 412-417
-
-
Sozio, P.1
Iannitelli, A.2
Cerasa, L.S.3
-
81
-
-
33144480459
-
L-Dopa- And dopamine-(R)-α-lipoic acid conjugates as multifunctional codrugs with antioxidant properties
-
DOI 10.1021/jm051145p
-
Di Stefano A, Sozio P, Cocco A, et al. L-Dopa- and Dopamine-(R)-α- Lipoic acid conjugates as multifunctional codrugs with antioxidant properties. J Med Chem 2006;49:1486-1493 (Pubitemid 43271901)
-
(2006)
Journal of Medicinal Chemistry
, vol.49
, Issue.4
, pp. 1486-1493
-
-
Di Stefano, A.1
Sozio, P.2
Cocco, A.3
Iannitelli, A.4
Santucci, E.5
Costa, M.6
Pecci, L.7
Nasuti, C.8
Cantalamessa, F.9
Pinnen, F.10
-
82
-
-
34248999408
-
Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties
-
DOI 10.1021/jm070037v
-
Pinnen F, Cacciatore I, Cornacchia C, et al. Synthesis and study of L-Dopa-Glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties. J Med Chem 2007;50:2506-2515 (Pubitemid 46799262)
-
(2007)
Journal of Medicinal Chemistry
, vol.50
, Issue.10
, pp. 2506-2515
-
-
Pinnen, F.1
Cacciatore, I.2
Cornacchia, C.3
Sozio, P.4
Iannitelli, A.5
Costa, M.6
Pecci, L.7
Nasuti, C.8
Cantalamessa, F.9
Di Stefano, A.10
-
83
-
-
0036460167
-
Dopamine agonists and neuroprotection in Parkinson's disease
-
DOI 10.1046/j.1468-1331.9.s3.9.x
-
Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol 2002;9:7-14 (Pubitemid 35471978)
-
(2002)
European Journal of Neurology
, vol.9
, Issue.SUPPL. 3
, pp. 7-14
-
-
Schapira, A.H.V.1
-
84
-
-
0037176885
-
Neuroprotection and dopamine agonists
-
Schapira AH. Neuroprotection and dopamine agonists. Neurology 2002;58:S9-S18
-
(2002)
Neurology
, vol.58
-
-
Schapira, A.H.1
-
85
-
-
0141856229
-
Neuroprotection in PD a role for dopamine agonists?
-
Schapira AH. Neuroprotection in PD a role for dopamine agonists? Neurology 2003;61:34-42
-
(2003)
Neurology
, vol.61
, pp. 34-42
-
-
Schapira, A.H.1
-
87
-
-
34248221738
-
Controversies of dopamine agonists: Somnolence, cardiac valvulopathy and repetitive behaviors
-
Jain S, Water CH. Controversies of dopamine agonists: somnolence, cardiac valvulopathy and repetitive behaviors. Curr Drug Ther 2007;2:17-20 (Pubitemid 46723134)
-
(2007)
Current Drug Therapy
, vol.2
, Issue.1
, pp. 17-20
-
-
Jain, S.1
Waters, C.H.2
-
88
-
-
0037208619
-
Are there clinically significant differences between dopamine agonists
-
Stocchi F, Vacca L, Onofrj M. Are there clinically significant differences between dopamine agonists. Adv Neurol 2003;91:259-266
-
(2003)
Adv Neurol
, vol.91
, pp. 259-266
-
-
Stocchi, F.1
Vacca, L.2
Onofrj, M.3
-
89
-
-
34548282615
-
Apomorphine in the treatment of Parkinson's disease
-
DOI 10.1517/14656566.8.12.1941
-
Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-1950 (Pubitemid 47321525)
-
(2007)
Expert Opinion on Pharmacotherapy
, vol.8
, Issue.12
, pp. 1941-1950
-
-
Menon, R.1
Stacy, M.2
-
91
-
-
0032851760
-
Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease
-
DOI 10.2165/00003088-199937030-00004
-
Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37:257-271 (Pubitemid 29452757)
-
(1999)
Clinical Pharmacokinetics
, vol.37
, Issue.3
, pp. 257-271
-
-
Neef, C.1
Van Laar, T.2
-
92
-
-
33744465789
-
Update on apomorphine for the rapid treatment of hypomobility ('Off') episodes in Parkinson's disease
-
DOI 10.1592/phco.26.6.840
-
Obering CD, Chen JJ, Swope DM. Update on apomorphine for the rapid treatment of hypomobility ('Off') episodes in Parkinson's Disease. Pharmacotherapy 2006;26:840-852 (Pubitemid 43807635)
-
(2006)
Pharmacotherapy
, vol.26
, Issue.6 I
, pp. 840-852
-
-
Obering, C.D.1
Chen, J.J.2
Swope, D.M.3
-
93
-
-
33748981339
-
Apomorphine: A rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease
-
DOI 10.1097/01.WNF.0000220824.57769.E5, PII 0000282620060900000008
-
Kolls BJ, Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson Disease. Clin Neuropharmacol 2006;29:292-301 (Pubitemid 44440003)
-
(2006)
Clinical Neuropharmacology
, vol.29
, Issue.5
, pp. 292-301
-
-
Kolls, B.J.1
Stacy, M.2
-
94
-
-
34249883912
-
Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose
-
DOI 10.1016/j.jns.2007.03.013, PII S0022510X07002158
-
Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007;258:137-143 (Pubitemid 46874490)
-
(2007)
Journal of the Neurological Sciences
, vol.258
, Issue.1-2
, pp. 137-143
-
-
Pahwa, R.1
Koller, W.C.2
Trosch, R.M.3
Sherry, J.H.4
-
95
-
-
43749088474
-
Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: A 6-month open-label study
-
• An investigation on the long-term efficacy and safety of apomorphine administered via subcutaneous route in advanced PD patients
-
Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study. CNS Drugs 2008;22(6):519-527 • An investigation on the long-term efficacy and safety of apomorphine administered via subcutaneous route in advanced PD patients.
-
(2008)
CNS Drugs
, vol.22
, Issue.6
, pp. 519-527
-
-
Trosch, R.M.1
Silver, D.2
Bottini, P.B.3
-
96
-
-
67649113810
-
-
website. Available from
-
Apokyn website. Available from: www.apokyn.com/
-
-
-
-
97
-
-
67649093740
-
-
website. Available from
-
Apo-go website. Available from: www.apo-go.co.uk/index.htm.
-
-
-
-
98
-
-
44249093494
-
Apomorphine for the acute treatment of 'off' episodes in Parkinson's disease
-
Stacya M, Silver D. Apomorphine for the acute treatment of 'off' episodes in Parkinson's disease. Parkinsonism Relat Disord 2008;14:85-92
-
(2008)
Parkinsonism Relat Disord
, vol.14
, pp. 85-92
-
-
Stacya, M.1
Silver, D.2
-
99
-
-
0036869028
-
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients
-
DOI 10.1002/mds.10281
-
Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's Disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-1241 (Pubitemid 36041337)
-
(2002)
Movement Disorders
, vol.17
, Issue.6
, pp. 1235-1241
-
-
Manson, A.J.1
Turner, K.2
Lees, A.J.3
-
100
-
-
20144366287
-
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges
-
DOI 10.1002/mds.20276
-
Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's Disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-157 (Pubitemid 40361117)
-
(2005)
Movement Disorders
, vol.20
, Issue.2
, pp. 151-157
-
-
Katzenschlager, R.1
Hughes, A.2
Evans, A.3
Manson, A.J.4
Hoffmann, M.5
Swinn, L.6
Watt, H.7
Bhatia, K.8
Quinn, N.9
Lees, A.J.10
-
101
-
-
52649108045
-
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's Disease with motor fluctuations: A multicenter study
-
García Ruiz PJ, Sesar Ignacio Á, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's Disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-1136
-
(2008)
Mov Disord
, vol.23
, pp. 1130-1136
-
-
García Ruiz, P.J.1
Sesar Ignacio, Á.2
Ares Pensado, B.3
-
102
-
-
0142186334
-
Continuous apomorphine infusion and neuropsychiatric disorders: A controlled study in patients with advanced Parkinson's disease
-
DOI 10.1007/s10072-003-0116-0
-
Di Rosa AE, Epifanio A, Antonini A, et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol Sci 2003;24:174-175 (Pubitemid 37304299)
-
(2003)
Neurological Sciences
, vol.24
, Issue.3
, pp. 174-175
-
-
Di Rosa, A.E.1
Epifanio, A.2
Antonini, A.3
Stocchi, F.4
Martino, G.5
Di Blasi, L.6
Tetto, A.7
Basile, G.8
Imbesi, D.9
La Spina, P.10
Di Raimondo, G.11
Morgante, L.12
-
103
-
-
3042647039
-
Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: A follow-up of two years
-
DOI 10.1016/j.archger.2004.04.039
-
Morgante L, Basile G, Epifanio A, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's Disease: a follow-up of two years. Arch Gerontol Geriatr 2004;9:291-296 (Pubitemid 38822878)
-
(2004)
Archives of Gerontology and Geriatrics
, vol.38
, Issue.SUPPL.
, pp. 291-296
-
-
Morgante, L.1
Basile, G.2
Epifanio, A.3
Spina, E.4
Antonini, A.5
Stocchi, F.6
Di Rosa, E.7
Martino, G.8
Marconi, R.9
La Spina, P.10
Nicita-Mauro, V.11
Di Rosa, A.E.12
-
104
-
-
1842575713
-
Practical considerations in the use of apomorphine injectable
-
Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004;62:S32-6 (Pubitemid 38419833)
-
(2004)
Neurology
, vol.62
, Issue.6 SUPPL. 4
-
-
Bowron, A.1
-
106
-
-
67649117493
-
-
Available from
-
Britannia products in developments. Available from: www.britannia-pharm. co.uk/partnerships.shtml#Apo-nasal%20PD.
-
Britannia Products in Developments
-
-
-
107
-
-
33748317921
-
Clinical studies with ropinirole in Parkinson's disease and RLS
-
DOI 10.1007/s00415-006-4004-4
-
Jost WH, Angersbach D, Rascol O. Clinical studies with ropinirole in Parkinson's disease and RLS. J Neurol 2006;253:16-21 (Pubitemid 44327086)
-
(2006)
Journal of Neurology
, vol.253
, Issue.SUPPL. 4
-
-
Jost, W.H.1
Angersbach, D.2
Rascol, O.3
-
108
-
-
30744474230
-
Ropinirole, a non-ergoline dopamine agonist
-
Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 2005;11:253-272
-
(2005)
CNS Drug Rev
, vol.11
, pp. 253-272
-
-
Jost, W.H.1
Angersbach, D.2
-
109
-
-
0033663588
-
Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease
-
Hubble J, Koller WC, Atchison P, et al. Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease. J Clin Pharmacol 2000;40:641-646
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 641-646
-
-
Hubble, J.1
Koller, W.C.2
Atchison, P.3
-
110
-
-
67649132254
-
-
website. Available from
-
RequipXL website. Available from: www.requipxl.com/
-
-
-
-
111
-
-
34147154059
-
Ropinirole 24-hour prolonged release. Randomized, controlled study in advanced Parkinson disease
-
• Evaluation of ropinirole 24-hour prolonged release as an adjunct to LD in patients with PD and motor fluctuations
-
Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release. Randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115 • Evaluation of ropinirole 24-hour prolonged release as an adjunct to LD in patients with PD and motor fluctuations.
-
(2007)
Neurology
, vol.68
, pp. 1108-1115
-
-
Pahwa, R.1
Stacy, M.A.2
Factor, S.A.3
-
112
-
-
44949178691
-
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease
-
DOI 10.2165/00023210-200822070-00003
-
Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008;22:563-586 (Pubitemid 351822118)
-
(2008)
CNS Drugs
, vol.22
, Issue.7
, pp. 563-586
-
-
Gallagher, D.A.1
Schrag, A.2
-
113
-
-
24144502098
-
Alternatives to levodopa in the initial treatment of early Parkinson's disease
-
DOI 10.2165/00002512-200522090-00002
-
Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005;22:731-740 (Pubitemid 41242117)
-
(2005)
Drugs and Aging
, vol.22
, Issue.9
, pp. 731-740
-
-
Lees, A.1
-
116
-
-
0036920178
-
Management of Parkinson's disease: An evidence-based review
-
Movement Disorders Society Evidence-Based Review
-
Movement Disorders Society Evidence-Based Review. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;7:1-166
-
(2002)
Mov Disord
, vol.7
, pp. 1-166
-
-
-
117
-
-
0030669245
-
Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: A double-blind, placebo-controlled, multicenter trial
-
Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the wearing off phenomenon: a double blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071 (Pubitemid 27456089)
-
(1997)
Neurology
, vol.49
, Issue.4
, pp. 1066-1071
-
-
Rajput, A.H.1
Martin, W.2
Saint-Hilaire, M.-H.3
Dorflinger, E.4
Pedder, S.5
-
118
-
-
0032547507
-
Tolcapone and fulminant hepatitis
-
Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998;352:958 (Pubitemid 28427283)
-
(1998)
Lancet
, vol.352
, Issue.9132
, pp. 958
-
-
Assal, F.1
Spahr, L.2
Hadengue, A.3
Rubbici-Brandt, L.4
Burkhard, P.R.5
-
119
-
-
19344378940
-
Entacapone in the treatment of Parkinson's disease
-
DOI 10.1016/S1474-4422(05)70098-3, PII S1474442205700983
-
Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005;4:366-370 (Pubitemid 40720033)
-
(2005)
Lancet Neurology
, vol.4
, Issue.6
, pp. 366-370
-
-
Schrag, A.1
-
120
-
-
0016414699
-
Potentiation of the anti-akinetic effect after L-Dopa treatment by an inhibitor of MAO-B, deprenil
-
Birkmayer W, Riederer P, Youdim MBH, et al. Potentiation of the anti-akinetic effect after L-Dopa treatment by an inhibitor of MAO-B, deprenil. J Neural Transm 1975;36:303-323
-
(1975)
J Neural Transm
, vol.36
, pp. 303-323
-
-
Birkmayer, W.1
Riederer, P.2
Youdim, M.B.H.3
-
121
-
-
0017345412
-
Implications of combined treatment with 'Madopar' and L deprenil in Parkinson's disease. a long term study
-
Birkmayer W, Riederer P, Ambrozi L, et al. Implications of combined treatment with Madopar and deprenil in Parkinson's disease; a long-term study. Lancet 1977;1:434-443 (Pubitemid 8045120)
-
(1977)
Lancet
, vol.1
, Issue.8009
, pp. 439-442
-
-
Birkmayer, W.1
Riederer, P.2
Ambroziyoudim, L.M.B.H.3
-
122
-
-
0017729733
-
Deprenyl in Parkinson's disease
-
Lees AJ, Shaw KM, Kohout LIJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2:791-795 (Pubitemid 8193248)
-
(1977)
Lancet
, vol.2
, Issue.8042
, pp. 791-795
-
-
Lees, A.J.1
Shaw, K.M.2
Kohout, L.J.3
-
123
-
-
0018840087
-
Deprenyl is selective inhibitor of brain MAO-B in the long-term treatment of Parkinson's disease
-
Reiderer P, Reynolds GP. Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinson's disease. Br J Clin Pharmacol 1980;9:98-99 (Pubitemid 10164684)
-
(1980)
British Journal of Clinical Pharmacology
, vol.9
, Issue.1
, pp. 98-99
-
-
Reiderer, P.1
Reynolds, G.P.2
-
124
-
-
0018068203
-
Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)deprenyl administration
-
Reynolds GP, Riederer P, Sandler M, et al. Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)deprenyl administration. J Neural Transm 1978;43:271-277 (Pubitemid 9050088)
-
(1978)
Journal of Neural Transmission - General Section
, vol.43
, Issue.3-4
, pp. 271-277
-
-
Reynolds, G.P.1
Riederer, P.2
Sandler, M.3
-
125
-
-
34247324279
-
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease
-
Lew MF, Pahwa R, Leehey M, et al. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin 2007;23:741-750
-
(2007)
Curr Med Res Opin
, vol.23
, pp. 741-750
-
-
Lew, M.F.1
Pahwa, R.2
Leehey, M.3
-
126
-
-
34848857679
-
Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms
-
DOI 10.1097/WNF.0b013e3180616570, PII 0000282620070900000007
-
Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms. Clin Neuropharmacol 2007;30:295-300 (Pubitemid 47511510)
-
(2007)
Clinical Neuropharmacology
, vol.30
, Issue.5
, pp. 295-300
-
-
Ondo, W.G.1
Sethi, K.D.2
Kricorian, G.3
-
127
-
-
2342426425
-
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study
-
DOI 10.1002/mds.20036
-
Waters CH, Sethi KD, Hause RA, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426-432 (Pubitemid 38559645)
-
(2004)
Movement Disorders
, vol.19
, Issue.4
, pp. 426-432
-
-
Waters, C.H.1
Sethi, K.D.2
Hauser, R.A.3
Molho, E.4
Bertoni, J.M.5
-
128
-
-
0345189359
-
A new formulation of selegiline: Improved bioavailability and selectivity for MAO-B inhibition
-
DOI 10.1007/s00702-003-0036-4
-
Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110:1241-1255 (Pubitemid 37500746)
-
(2003)
Journal of Neural Transmission
, vol.110
, Issue.11
, pp. 1241-1255
-
-
Clarke, A.1
Brewer, F.2
Johnson, E.S.3
Mallard, N.4
Hartig, F.5
Taylor, S.6
Corn, T.H.7
-
129
-
-
0344758978
-
A new low-dose formulation of selegiline: Clinical efficacy, patient preference and selectivity for MAO-B inhibition
-
DOI 10.1007/s00702-003-0042-6
-
Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 2003;110:1257-1271 (Pubitemid 37500747)
-
(2003)
Journal of Neural Transmission
, vol.110
, Issue.11
, pp. 1257-1271
-
-
Clarke, A.1
Johnson, E.S.2
Mallard, N.3
Corn, T.H.4
Johnston, A.5
Boyce, M.6
Warrington, S.7
MacMahon, D.G.8
-
130
-
-
0030300167
-
Pharmacology and neuroprotective properties of rasagiline
-
Finberg JPM, Lamensdorf I, Commissiong JW, et al. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm 1996;48:95-101 (Pubitemid 26423350)
-
(1996)
Journal of Neural Transmission, Supplement
, Issue.48
, pp. 95-101
-
-
Finberg, J.P.M.1
Lamensdorf, I.2
Commissiong, J.W.3
Youdim, M.B.H.4
-
131
-
-
0036894795
-
A controlled trial of rasagiline in early Parkinson disease: The tempo study
-
DOI 10.1001/archneur.59.12.1937
-
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. the TEMPO Study. Arch Neurol 2002;59:1937-1943 (Pubitemid 35424653)
-
(2002)
Archives of Neurology
, vol.59
, Issue.12
, pp. 1937-1943
-
-
Siderowf, A.1
Stern, M.2
Shoulson, I.3
Kieburtz, K.4
Oakes, D.5
Day, D.6
Shinaman, A.7
Plumb, S.8
Fahn, S.9
Blindauer, K.10
Lew, M.11
Hurtig, H.12
Lloyd, M.13
Hauser, R.14
Gauger, L.15
Golbe, L.16
Wojcieszek, J.17
Belden, J.18
Feigin, A.19
Klimek, M.L.20
Shannon, B.21
Ondo, W.22
Hunter, C.23
Calabrese, V.24
Atchison, P.25
Allen, C.26
Marshall, F.27
Berry, D.28
Gardiner, I.29
Miyasaki, J.30
Del Rizzo, L.31
Mendis, T.32
Mendis, N.33
Gray, P.34
Hubble, J.35
Betcher, K.36
Pahwa, R.37
Molho, E.38
Brown, D.39
Shulman, L.40
Rajput, A.41
Ewanishin, M.42
Stacy, M.43
Williamson, K.44
Bertoni, J.45
Peterson, C.46
Tuite, P.47
Ebbitt, B.48
Shannon, K.49
Jaglin, J.50
Tanner, C.51
Marek, K.52
Stavris, K.53
Aminoff, M.J.54
Diminno, M.55
Dowling, G.56
Kang, U.J.57
Richman, J.58
Sethi, K.59
Martin, W.60
King, P.61
McInnes, G.62
Adler, C.63
Lewitt, P.64
Deangelis, M.65
Schear, M.66
Gordon, M.F.67
Winnick, R.68
Feldman, R.69
Thomas, C.-A.70
Conn, K.71
Brocht, A.72
Chadwick, C.73
Connolly, J.74
Daigneault, S.75
Eberly, S.76
Bausch, J.77
Josephson, L.78
Oliva, R.79
Schwid, S.80
Lang, A.81
Cox, C.82
Irvine, C.83
Nutt, J.84
White, W.85
Oren, S.86
Levy, R.87
Eyal, E.88
Ladkani, D.89
Houck, W.90
more..
-
132
-
-
15844386001
-
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial
-
DOI 10.1016/S0140-6736(05)71083-7, PII S0140673605710837
-
Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954 (Pubitemid 41071428)
-
(2005)
Lancet
, vol.365
, Issue.9463
, pp. 947-954
-
-
Rascol, O.1
Brooks, D.J.2
Melamed, E.3
Oertel, W.4
Poewe, W.5
Stocchi, F.6
Tolosa, E.7
-
133
-
-
13444302612
-
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study
-
DOI 10.1001/archneur.62.2.241
-
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch Neurol 2005;62:241-248 (Pubitemid 40204745)
-
(2005)
Archives of Neurology
, vol.62
, Issue.2
, pp. 241-248
-
-
Schwid, S.R.1
-
134
-
-
0037734329
-
Neuroprotection by deprenyl and other propargylamines: Glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B
-
DOI 10.1007/s00702-002-0827-z
-
Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003;110:509-515 (Pubitemid 36543282)
-
(2003)
Journal of Neural Transmission
, vol.110
, Issue.5
, pp. 509-515
-
-
Tatton, W.1
Chalmers-Redman, R.2
Tatton, N.3
-
135
-
-
0036229947
-
Propargylamines induce antiapoptotic new protein synthesis in serum- And nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells
-
DOI 10.1124/jpet.301.2.753
-
Tatton WG, Chalmers-Redman RM, Ju WJ, et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 2002;301:753-764 (Pubitemid 34429993)
-
(2002)
Journal of Pharmacology and Experimental Therapeutics
, vol.301
, Issue.2
, pp. 753-764
-
-
Tatton, W.G.1
Chalmers-Redman, R.M.E.2
Ju, W.J.H.3
Mammen, M.4
Carlile, G.W.5
Pong, A.W.6
Tatton, N.A.7
-
136
-
-
61449173973
-
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's Disease (The ADAGIO Study): Rationale, design, and baseline characteristics
-
Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's Disease (The ADAGIO Study): rationale, design, and baseline characteristics. Mov Disord 2008;23:2194-2201
-
(2008)
Mov Disord
, vol.23
, pp. 2194-2201
-
-
Olanow, C.W.1
Hauser, R.A.2
Jankovic, J.3
-
138
-
-
0026751312
-
Amantadine as a N-methyl-D-aspartic acid receptor antagonist: New possibilities for therapeutic application?
-
Stoof JC, Booij J, Drukarch B. Amantadine as a N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic application? Clin Neurol Neurosurg 1992;92:S4-6
-
(1992)
Clin Neurol Neurosurg
, vol.92
-
-
Stoof, J.C.1
Booij, J.2
Drukarch, B.3
-
139
-
-
22544444943
-
A novel dopamine agonist for the transdermal treatment of Parkinson's disease
-
Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005;65:3-5 (Pubitemid 41022399)
-
(2005)
Neurology
, vol.65
, Issue.2 SUPPL. 1
-
-
Jenner, P.1
-
140
-
-
0028324501
-
2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease
-
Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994;9:147-154 (Pubitemid 24092329)
-
(1994)
Movement Disorders
, vol.9
, Issue.2
, pp. 147-154
-
-
Belluzzi, J.D.1
Domino, E.F.2
May, J.M.3
Bankiewicz, K.S.4
McAfee, D.A.5
-
141
-
-
34247208187
-
Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
-
DOI 10.1212/01.wnl.0000259516.61938.bb, PII 0000611420070417000008
-
LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system PREFER Study. Neurology 2007;68:1262-1267 (Pubitemid 46625971)
-
(2007)
Neurology
, vol.68
, Issue.16
, pp. 1262-1267
-
-
Lewitt, P.A.1
Lyons, K.E.2
Pahwa, R.3
-
142
-
-
33846438955
-
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
-
DOI 10.1212/01.wnl.0000252355.79284.22, PII 0000611420070123000009
-
Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-276 (Pubitemid 46148338)
-
(2007)
Neurology
, vol.68
, Issue.4
, pp. 272-276
-
-
Watts, R.L.1
Jankovic, J.2
Waters, C.3
Rajput, A.4
Boroojerdi, B.5
Rao, J.6
-
143
-
-
34248372064
-
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomised controlled trial
-
DOI 10.1016/S1474-4422(07)70108-4, PII S1474442207701084
-
Poewe WH, Rascol O, Quinn N, et al. The SP 515 Investigators, efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomized controlled trial. Lancet Neurol 2007;6:513-520 (Pubitemid 46734759)
-
(2007)
Lancet Neurology
, vol.6
, Issue.6
, pp. 513-520
-
-
Poewe, W.H.1
Rascol, O.2
Quinn, N.3
Tolosa, E.4
Oertel, W.H.5
Martignoni, E.6
Rupp, M.7
Boroojerdi, B.8
-
144
-
-
33748753171
-
Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: Subanalysis of a parallel group, open-label, dose-escalation study
-
DOI 10.1097/01.WNF.0000228179.83335.65, PII 0000282620060700000009
-
Babic T, Boothmann B, Polivka J, et al. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin Neuropharmacol 2006;29:238-242 (Pubitemid 44510461)
-
(2006)
Clinical Neuropharmacology
, vol.29
, Issue.4
, pp. 238-242
-
-
Babic, T.1
Boothmann, B.2
Polivka, J.3
Rektor, I.4
Boroojerdi, B.5
Hack, H.-J.6
Randerath, O.7
-
145
-
-
0034971541
-
Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease
-
DOI 10.1097/00002826-200105000-00008
-
Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001;2:163-169 (Pubitemid 32549992)
-
(2001)
Clinical Neuropharmacology
, vol.24
, Issue.3
, pp. 163-169
-
-
Metman, L.V.1
Gillespie, M.2
Farmer, C.3
Bibbiani, F.4
Konitsiotis, S.5
Morris, M.6
Shill, H.7
Bara-Jimenez, W.8
Mouradian, M.M.9
Chase, T.N.10
-
146
-
-
0035353743
-
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study
-
Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001;16:459-463
-
(2001)
Mov Disord
, vol.16
, pp. 459-463
-
-
Hutton, J.T.1
Metman, L.V.2
Chase, T.N.3
-
147
-
-
34249033784
-
Transdermal rotigotine: Double-blind, placebo-controlled trial in Parkinson disease
-
DOI 10.1001/archneur.64.5.676
-
Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007;64:676-682 (Pubitemid 46789833)
-
(2007)
Archives of Neurology
, vol.64
, Issue.5
, pp. 676-682
-
-
Jankovic, J.1
Watts, R.L.2
Martin, W.3
Boroojerdi, B.4
-
148
-
-
21544434051
-
Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease
-
DOI 10.1097/01.wnf.0000162228.00154.ba
-
Gueldenpfennig WM, Poole KH, Sommerville KW, et al. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson Disease. Clin Neuropharmacol 2005;28:106-110 (Pubitemid 40923407)
-
(2005)
Clinical Neuropharmacology
, vol.28
, Issue.3
, pp. 106-110
-
-
Guldenpfennig, W.M.1
Poole, K.H.2
Sommerville, K.W.3
Boroojerdi, B.4
-
149
-
-
67649123875
-
-
website. Available from: Last accessed 21 March 2008
-
Neupro website. Available from: www.neupro.com/Home/Home.asp [Last accessed 21 March 2008]
-
-
-
-
150
-
-
33846469933
-
Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease
-
DOI 10.1016/j.expneurol.2006.08.026, PII S0014488606005279
-
Scheller D, Chan P, Li Q, et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol 2007;203:415-422 (Pubitemid 46151765)
-
(2007)
Experimental Neurology
, vol.203
, Issue.2
, pp. 415-422
-
-
Scheller, D.1
Chan, P.2
Li, Q.3
Wu, T.4
Zhang, R.5
Guan, L.6
Ravenscroft, P.7
Guigoni, C.8
Crossman, A.R.9
Hill, M.10
Bezard, E.11
-
151
-
-
38749085263
-
Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease
-
• Investigation on potential neuroprotective property of rotigotine in MPTP-lesioned animal
-
Scheller D, Stichel-Gunkel C, Lübbert H, et al. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neurosci Lett 2008;432:30-34 • Investigation on potential neuroprotective property of rotigotine in MPTP-lesioned animal
-
(2008)
Neurosci Lett
, vol.432
, pp. 30-34
-
-
Scheller, D.1
Stichel-Gunkel, C.2
Lübbert, H.3
-
152
-
-
0033934595
-
Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease
-
Allain H, Destée A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. Eur Neurol 2000;44:22-30 (Pubitemid 30456788)
-
(2000)
European Neurology
, vol.44
, Issue.1
, pp. 22-30
-
-
Allain, H.1
Destee, A.2
Petit, H.3
Patay, M.4
Schuck, S.5
Bentue-Ferrer, D.6
Le Cavorzin, P.7
-
153
-
-
0031816729
-
Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease
-
Hayashi R, Tako K, Mikashita H, et al. Efficacy of low-dose lisuride infusion in Parkinson's disease. Intern Med 1998;37:444-448 (Pubitemid 28316985)
-
(1998)
Internal Medicine
, vol.37
, Issue.5
, pp. 444-448
-
-
Hayashi, R.1
Tako, K.2
Makishita, H.3
Koyama, J.4
Yanagisawa, N.5
-
154
-
-
0026668816
-
Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease
-
Heinz A, Suchy I, Klewin I, et al. Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease. J Neural Transm 1992;4:291-301
-
(1992)
J Neural Transm
, vol.4
, pp. 291-301
-
-
Heinz, A.1
Suchy, I.2
Klewin, I.3
-
155
-
-
4544326052
-
Transdermal lisuride delivery in the treatment of Parkinson's disease
-
Woitalla D, Müller T, Benz S, et al. Transdermal lisuride delivery in the treatment of Parkinson's disease. J Neural Transm Suppl 2004;68:89-95 (Pubitemid 39215441)
-
(2004)
Journal of Neural Transmission, Supplement
, Issue.68
, pp. 89-95
-
-
Woitalla, D.1
Muller, T.2
Benz, S.3
Horowski, R.4
Przuntek, H.5
-
156
-
-
0026457051
-
Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease
-
Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781
-
(1992)
Ann Neurol
, vol.32
, pp. 776-781
-
-
Baronti, F.1
Mouradian, M.M.2
Davis, T.L.3
-
157
-
-
0025972525
-
Subcutaneous lisuride infusion in Parkinson's disease: Response to chronic administration in 34 patients
-
Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in
-
(1991)
Brain
, vol.114
, pp. 601-617
-
-
Vaamonde, J.1
Luquin, M.R.2
Obeso, J.A.3
-
158
-
-
0036723589
-
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease
-
Stocchi F, Ruggieri S, Vacca L, et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125:2058-2066 (Pubitemid 34940716)
-
(2002)
Brain
, vol.125
, Issue.9
, pp. 2058-2066
-
-
Stocchi, F.1
Ruggieri, S.2
Vacca, L.3
Olanow, C.W.4
-
159
-
-
0027354148
-
Apomorphine and lisuride infusion: A comparative chronic study
-
Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion: a comparative chronic study. Adv Neurol 1993;60:653-655
-
(1993)
Adv Neurol
, vol.60
, pp. 653-655
-
-
Stocchi, F.1
Bramante, L.2
Monge, A.3
-
160
-
-
0024257549
-
Comparison between L-dopa and lisuride intravenous infusions: A clinical study
-
Ruggieri S, Stocchi F, Carta A, et al. Comparison between L-dopa and lisuride intravenous infusions: a clinical study. Mov Disord 1988;3:313-319
-
(1988)
Mov Disord
, vol.3
, pp. 313-319
-
-
Ruggieri, S.1
Stocchi, F.2
Carta, A.3
-
161
-
-
33750802483
-
Maleic- And fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation
-
DOI 10.1080/10611860600916636, PII U336L07V66514554
-
Di Stefano A, Sozio P, Iannitelli A, et al. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation. J Drug Target 2006;14:652-661 (Pubitemid 44712361)
-
(2006)
Journal of Drug Targeting
, vol.14
, Issue.9
, pp. 652-661
-
-
Di Stefano, A.1
Sozio, P.2
Iannitelli, A.3
Marianecci, C.4
Santucci, E.5
Carafa, M.6
-
162
-
-
11144313645
-
Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC
-
DOI 10.1016/j.jpba.2004.09.029, PII S0731708504004431
-
Cannazza G, Di Stefano A, Mosciatti B, et al. Detection of L-DOPA, Dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC. J Pharm Biomed Anal 2005;36:1079-1084 (Pubitemid 40037829)
-
(2005)
Journal of Pharmaceutical and Biomedical Analysis
, vol.36
, Issue.5
, pp. 1079-1084
-
-
Cannazza, G.1
Di Stefano, A.2
Mosciatti, B.3
Braghiroli, D.4
Baraldi, M.5
Pinnen, F.6
Sozio, P.7
Benatti, C.8
Parenti, C.9
-
163
-
-
4544352872
-
Evaluation of rat striatal l-dopa and DA concentration after intraperitoneal administration of l-dopa prodrugs in liposomal formulations
-
DOI 10.1016/j.jconrel.2004.07.010, PII S0168365904003219
-
Di Stefano A, Carafa M, Sozio P, et al. Evaluation of rat striatal L-Dopa and DA concentration after intraperitoneal administration of L-Dopa prodrugs in liposomal formulations. J Control Release 2004;99:293-300 (Pubitemid 39222114)
-
(2004)
Journal of Controlled Release
, vol.99
, Issue.2
, pp. 293-300
-
-
Di Stefano, A.1
Carafa, M.2
Sozio, P.3
Pinnen, F.4
Braghiroli, D.5
Orlando, G.6
Cannazza, G.7
Ricciutelli, M.8
Marianecci, C.9
Santucci, E.10
-
164
-
-
44749092720
-
Solid lipid nanoparticles as delivery systems for Bromocriptine
-
Esposito E, Fantin M, Marti M, et al. Solid lipid nanoparticles as delivery systems for Bromocriptine. Pharm Res 2008;25:1521-1530
-
(2008)
Pharm Res
, vol.25
, pp. 1521-1530
-
-
Esposito, E.1
Fantin, M.2
Marti, M.3
-
165
-
-
0021586266
-
A new class of polymers: Starburst-dendritic macromolecules
-
Tomalia DA, Baker H, Dewald J, et al. A new class of polymers: starburst-dendritic macromolecules. Polym J 1985;17:117-132
-
(1985)
Polym J
, vol.17
, pp. 117-132
-
-
Tomalia, D.A.1
Baker, H.2
Dewald, J.3
-
166
-
-
0025373701
-
Starbust dendrimers: Molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter
-
Tomalia DA, Naylor AM, Goddard WA. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 1990;29:138-175 (Pubitemid 20142204)
-
(1990)
Angewandte Chemie - International Edition in English
, vol.29
, Issue.2
, pp. 138-175
-
-
Tomalia, D.A.1
Naylor, A.M.2
Goddard III, W.A.3
-
167
-
-
33750080477
-
Synthesis and characterization of water-soluble and photostable L-DOPA dendrimers
-
DOI 10.1021/ol061449l
-
Tang S, Martinez LJ, Sharma MA, et al. Synthesis and characterization of water-soluble and photostable L-DOPA dendrimers. Org Lett 2006;8:4421-4424 (Pubitemid 44578642)
-
(2006)
Organic Letters
, vol.8
, Issue.20
, pp. 4421-4424
-
-
Tang, S.1
Martinez, L.J.2
Sharma, A.3
Chai, M.4
-
168
-
-
0034095651
-
Transport of drugs from the nasal cavity to the central nervous system
-
DOI 10.1016/S0928-0987(00)00087-7, PII S0928098700000877
-
Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18 (Pubitemid 30410839)
-
(2000)
European Journal of Pharmaceutical Sciences
, vol.11
, Issue.1
, pp. 1-18
-
-
Illum, L.1
-
169
-
-
3242740239
-
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration
-
DOI 10.1016/j.neuroscience.2004.05.029, PII S0306452204004002
-
Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insuline-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-496 (Pubitemid 38950662)
-
(2004)
Neuroscience
, vol.127
, Issue.2
, pp. 481-496
-
-
Thorne, R.G.1
Pronk, G.J.2
Padmanabhan, V.3
Frey II, W.H.4
-
170
-
-
0025903316
-
Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity
-
Sakane T, Akizuki M, Yoshida M, et al. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol 1991;43:449-451
-
(1991)
J Pharm Pharmacol
, vol.43
, pp. 449-451
-
-
Sakane, T.1
Akizuki, M.2
Yoshida, M.3
-
171
-
-
0025944792
-
The transport of drugs to the cerebrospinal fluid directly from the nasal cavity: The relation to the lipophilicity of the drug
-
Sakane T, Akizuki M, Yamashita S, et al. The transport of drugs to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 1991;39:2456-2458
-
(1991)
Chem Pharm Bull
, vol.39
, pp. 2456-2458
-
-
Sakane, T.1
Akizuki, M.2
Yamashita, S.3
-
172
-
-
0020317797
-
Pharmacokinetics of progesterone after its administration to ovariectomized rhesus monkeys by injection, infusion, or nasal spraying
-
DOI 10.1073/pnas.79.13.4185
-
Kumar TA, David GFX, Sankaranarayanan A, et al. Pharmacokinetics of progesterone after its administration to ovariectomized rhesus monkeys by injection, infusion, or nasal spraying. Proc Natl Acad Sci 1982;79:4185-4189 (Pubitemid 12035102)
-
(1982)
Proceedings of the National Academy of Sciences of the United States of America
, vol.79
, Issue.13
, pp. 4185-4189
-
-
Anand Kumar, T.C.1
David, G.F.X.2
Sankaranarayanan, A.3
-
173
-
-
0033795553
-
Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs
-
DOI 10.1023/A:1007583422634
-
Kao HD, Traboulsi A, Itoh S, et al. Enhancement of the systemic and CNS specific delivery of L-Dopa by the nasal administration of its water soluble prodrugs. Pharm Res 2000;17:978-984 (Pubitemid 30736602)
-
(2000)
Pharmaceutical Research
, vol.17
, Issue.8
, pp. 978-984
-
-
Kao, H.D.1
Traboulsi, A.2
Itoh, S.3
Dittert, L.4
Hussain, A.5
-
174
-
-
3343000150
-
A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease
-
DOI 10.1124/jpet.103.064121
-
Bartus RT, Emerich D, Snodgrass-Belt P, et al. Pulmonary formulation of L-Dopa enhances its effectiveness in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2004;310:828-835 (Pubitemid 38988931)
-
(2004)
Journal of Pharmacology and Experimental Therapeutics
, vol.310
, Issue.2
, pp. 828-835
-
-
Bartus, R.T.1
Emerich, D.2
Snodgrass-Belt, P.3
Fu, K.4
Salzberg-Brenhouse, H.5
Lafreniere, D.6
Novak, L.7
Lo, E.-S.8
Cooper, T.9
Basile, A.S.10
-
175
-
-
67649113813
-
-
Schwarz Pharma press release for Parcopa® aprroval from PDA. Available from
-
Schwarz Pharma press release for Parcopa® aprroval from PDA. Available from: www.schwarzpharma.com/sp/n2345/Press-Release--August-30-2004
-
-
-
-
176
-
-
67649117495
-
-
website. Available from
-
Stalevo website. Available from: www.stalevo.com
-
-
-
-
177
-
-
67649132258
-
-
Information on V1512. Available from
-
Information on V1512. Available from: www.vernalis.com/ver/rdc2/ neurology/v1512/
-
-
-
-
178
-
-
33846837447
-
Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease
-
DOI 10.1097/01.WNF.0000236762.77913.C6, PII 0000282620070100000004
-
Stocchi F, Fabbri L, Vecsei L, et al. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007;30:18-24 (Pubitemid 46204314)
-
(2007)
Clinical Neuropharmacology
, vol.30
, Issue.1
, pp. 18-24
-
-
Stocchi, F.1
Fabbri, L.2
Vecsei, L.3
Krygowska-Wajs, A.4
Monici Preti, P.A.5
Ruggieri, S.A.6
-
181
-
-
67649085495
-
-
website. Available from
-
Tasmar website. Available from: www.tasmar.com
-
-
-
-
182
-
-
67649098962
-
-
website. Available from
-
Comtan website. Available from: www.comtan.com
-
-
-
-
183
-
-
67649083305
-
-
Available from
-
Eldepryl information. Available from: www.somersetpharm.com/products/
-
Eldepryl Information
-
-
-
184
-
-
67649116054
-
-
website. Available from
-
Zelapar website. Available from: www.zelapar.com
-
-
-
-
185
-
-
67649134578
-
-
website. Available from
-
Azilect website. Available from: www.azilect.com
-
-
-
-
186
-
-
33750000049
-
Symptom relief in Parkinson's disease by safinamide. Biochemical and clinical evidence of efficacy beyond MAO-B inhibition
-
Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson's disease by safinamide. Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67:24-29
-
(2006)
Neurology
, vol.67
, pp. 24-29
-
-
Stocchi, F.1
Vacca, L.2
Grassini, P.3
-
188
-
-
67649092120
-
-
website. Available from
-
Mirapex website. Available from: www.mirapex.com/
-
-
-
-
189
-
-
67649128105
-
-
website. Available from
-
Requip website. Available from: www.requip.com/
-
-
-
-
190
-
-
67649093747
-
-
website. Available from
-
Aderis Pharmaceuticals website. Available from: www.aderis.com/products/ rotigotine.htm
-
-
-
-
193
-
-
67649132259
-
-
Available from
-
Information on amantadine. Available from: www.endo.com/PDF/symmetrel- pack-insert.pdf
-
Information on Amantadine
-
-
|